Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Multimodal Intervention for Cachexia in Advanced Cancer Patients Undergoing Chemotherapy
NCT02330926 · View on ClinicalTrials.gov ↗
Study Summary
Cancer cachexia is a multi-factorial syndrome defined by an ongoing loss of skeletal muscle mass (with or without loss of fat mass) that cannot be fully reversed by conventional nutritional support and leads to progressive functional impairment. There is an urgency for improving management, but there is no consensus on the optimal treatment for cancer cachexia. Several single therapies for cancer cachexia have been examined in clinical trials, with disappointing overall results. As multiple factors are responsible for the development of cachexia, it has been argued that optimal cachexia interventions should target all components: multimodal therapy for a multimodal problem. The overall aim of this study is to early prevent the development of cachexia rather than treatment late in the disease trajectory. From a patient perspective a short term effect will be to improve physical and psychological function, to reduce symptom burden and to improve survival. In other words live a longer and better life during and after chemotherapy. Direct effects of the cachexia intervention are expected to be reduction of weight and muscle loss, and improved physical activity and quality of life.
Interventions
- DRUG Ibuprofen
- OTHER standard care
- DIETARY_SUPPLEMENT nutritional supplements and advice
- BEHAVIORAL home-based self-assisted exercise program
Study Locations (17)
Other
- CA4 Brampton Civic Hospital — Brampton
- Cross Cancer Insitute — Edmonton
- Jewish General Hospital — Montreal
- Ottawa Regional Cancer Centre — Ottawa
- Universitätsklinikum Bonn — Bonn
- Oslo University Hospital — Oslo
- St Olavs Hospital — Trondheim
- Tumor Zentrum — Aarau
- Cantonal Hospital — Sankt Gallen
- Llandough Hospital — Cardiff
- Edinburgh Cancer Centre — Edinburgh
- Beatson West of Scotland Cancer Centre — Glasgow
- Chelsea and Westminister Hospital NHS — London
- Guys and St Thomas — London
California
- Cedars-Sinai Medical Center — Los Angeles
Falkirk
- NHS Forth Valley — Larbert
Fife
- Queen Margaret Hospital — Dunfermline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 221 participants |
| Start Date | 2015-04 |
| Est. Completion | 2023-04 |
| Phase | Phase 3 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02330926
The ClinicalTrials.gov registry entry for NCT02330926 describes a study currently listed as completed. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 221 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Norwegian University of Science and Technology, which has 1 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 2 conditions, with Neoplasms appearing as the primary indexed condition, and to 4 interventions — of which Ibuprofen is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT02330926 reports 17 study locations spanning 4 distinct geographic areas — top geographies include Other, California, Falkirk. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT02330926 about?
NCT02330926 is a clinical study titled "Multimodal Intervention for Cachexia in Advanced Cancer Patients Undergoing Chemotherapy". Cancer cachexia is a multi-factorial syndrome defined by an ongoing loss of skeletal muscle mass (with or without loss of fat mass) that cannot be fully reversed by conventional nutritional support and leads to progressive functional impairment. There is an urgency for improving management, but the...
What is the current status of trial NCT02330926?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 221 participants. The study started on 2015-04. Estimated completion is 2023-04.
What conditions does trial NCT02330926 study?
This clinical trial studies the following conditions: Neoplasms, Cachexia. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT02330926?
The interventions under investigation include: Ibuprofen (DRUG), standard care (OTHER), nutritional supplements and advice (DIETARY_SUPPLEMENT), home-based self-assisted exercise program (BEHAVIORAL). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT02330926?
This trial is sponsored by Norwegian University of Science and Technology, which has 1 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT02330926 being conducted?
This trial has 17 study locations across California, Falkirk, Fife. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.